It appears our article yesterday morning on Trulieve Cannabis (CSE: TRUL) insider selling was slightly.. premature. While we reported that director Michael O’Donnell was the sole director that had sold equity in the company as of late, at a total sales figure of $5,667,857, it turns out that we published the article to early.
The reason for this, is additional directors of the company have also since filed their sales transactions, with CFO Alexander D’Amico remaining the only insider to purchase securities. Further, it appears that O’Donnell’s reported sale of securities was the final one to occur, with three other directors selling shares on the open market two days ahead of him, on August 17.
The total open market securities sales by Trulieve directors during the week of August 17, 2020 breakdown as follows:
Sponsored · Emerita Resources Corp.
- Thad Beshears – Sold 585,000 shares at a price of $20.41, for gross proceeds of $11,939,850
- George Hackney – Sold 194,445 shares at a price of $20.41 for gross proceeds of $3,968,622.45
- Richard May – Sold 75,219 shares at a price of $20.41 for gross proceeds of $1,535,219.79
- Michael O’Donnell – As previously reported, sold 277,700 shares at a price of $20.41 for gross proceeds of $5,667,857
Collectively, the directors of the company sold a total of 1,132,364 shares on the open markets, for gross proceeds of $23,111,549.24. Meanwhile, total insider purchases amount to 1,500 shares of the issuer, worth $31,900.
Perhaps the most interesting aspect of the transactions, is that the data does not line up with the markets. On the Canadian markets, sales on the open market on August 17 hit a low price of $30.99 – more than $10 higher than the reported sales price for shares that the insiders sold.
On the US side (figures reported above should, theoretically, be in Canadian Dollars), the low was $23.49 – still above the reported transaction price of $20.41 for each and every insider sale. Similarly, on August 19, the other day of reported insider sales, the low on the US side was $21.50 whereas the Canadian markets saw a low of $29.00.
Trulieve Cannabis last traded at $26.89 on the CSE.
Information for this briefing was found via Sedar and Trulieve Cannabis Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
